Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

Kelly Anne Phillips, Karin Ribi, Zhuoxin Sun, Alisa Stephens, Alastair Thompson, Vernon Harvey, Beat Thürlimann, Fatima Cardoso, Olivia Pagani, Alan S. Coates, Aron Goldhirsch, Karen N. Price, Richard D. Gelber, Jürg Bernhard

Research output: Contribution to journalArticlepeer-review

Abstract

Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial. In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tamoxifen. The primary comparison was the difference in composite score for patients taking letrozole (B + C; N=65) vs. tamoxifen (A + D; N=55). The patients taking letrozole had better overall cognitive function than those taking tamoxifen (difference in mean composite z-scores=0.28, P=0.04, 95% CI: 0.02, 0.54, Cohen's D=0.40 indicating small to moderate effect). In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen.

Original languageEnglish
Pages (from-to)388-395
Number of pages8
JournalBreast
Volume19
Issue number5
DOIs
Publication statusPublished - Oct 2010

Keywords

  • Aromatase inhibitor
  • Breast cancer
  • Cognitive function
  • Letrozole
  • Quality of life
  • Tamoxifen

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial'. Together they form a unique fingerprint.

Cite this